PEER / The Swygert Axis: A Unified Model of Cytokine-Histamine Dysregulation and Immune Equilibrium
PEER / The Swygert Axis: A Unified Model of Cytokine-Histamine Dysregulation and Immune Equilibrium
Author: John Stephen Swygert
Submission Date: August 25, 2025
Abstract
The Swygert Axis presents a novel diagnostic and therapeutic framework for chronic inflammatory diseases, integrating histamine receptor signaling (H1–H4), cytokine dynamics, mast cell activation, and viral latency. Rooted in the author’s 15+ years of lived experience and guided by the TSTOEAO philosophy (V = EY: Realized Value = Equilibrium Rule × Opportunity), it posits that conditions such as long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia, and others arise from a dysregulated immune axis overwhelmed by cumulative antigenic burden. This model proposes layered interventions—receptor-specific antihistamines, anti-cytokine agents, and antivirals—as a low-cost, reproducible strategy to restore immune equilibrium, validated by case evidence and emerging clinical data.
1. Introduction
Chronic inflammatory diseases, including long COVID, ME/CFS, fibromyalgia, postural orthostatic tachycardia syndrome (POTS), and cutaneous syndromes, often elude conventional diagnosis due to their multi-systemic nature. The Swygert Axis, inspired by The Self-Taught Origin of Everything and One (TSTOEAO)—a philosophy emphasizing self-derived insight, holistic integration, and equilibrium as a universal law—reframes these conditions as a cascading collapse of an immune-neurovascular axis. Born from the author’s 15+ years of undiagnosed suffering, this model challenges fragmented medical approaches, offering a unified framework for researchers, clinicians, and patients.
2. Biological Basis of the Swygert Axis
2.1 Histamine Receptors (H1–H4)
Histamine, a pivotal immune modulator, operates through four receptors:
H1R: Mediates allergic responses, vascular permeability, and nerve hypersensitivity, manifesting as skin inflammation [1].
H2R: Regulates gastric acid secretion, immune cell function, and cardiac rhythm, contributing to gut and vascular dysfunction [2].
H3R: Modulates neurotransmitter release (e.g., dopamine, serotonin), linked to neuroinflammation and fatigue states [3].
H4R: Expressed on mast cells and eosinophils, drives chemotaxis and chronic immune activation [4,5].
Together, these form a quadruple lever system governing immune equilibrium.
2.2 Cytokine Signaling and Mast Cell Activation
Histamine receptors amplify pro-inflammatory cytokines (e.g., IL-6, TNF-α) in a feedback loop, sustaining inflammation [6]. Mast cells, activated by H4R, release histamine and cytokines, perpetuating systemic dysfunction [7]. This crosstalk is the axis’s core mechanism.
2.3 Viral Latency and Pathogen Triggers
Latent herpesviruses (HSV-1, EBV, CMV, VZV) reactivate under immune stress, triggering cytokine release via NF-κB pathways [8]. Other pathogens—fungi (Candida), bacteria (Porphyromonas gingivalis), parasites, and environmental irritants (dust, chemicals)—contribute to an antigenic burden, amplifying axis dysregulation.
3. Model of Collapse: Cumulative Burden
Guided by TSTOEAO’s holistic lens, the Swygert Axis models chronic illness as a failure of immune homeostasis due to cumulative insults—viral reactivation, toxins, stress, or genetic predispositions (e.g., impaired methylation). This creates a self-perpetuating cycle, manifesting as long COVID, ME/CFS, POTS, or cutaneous syndromes (Figure 1).Figure 1: The Swygert Axis Cycle (Description): A feedback loop where H1R sparks skin/nerve inflammation, H2R disrupts gut/cardiac function, H3R fuels neuroinflammation, and H4R amplifies mast cell activity and cytokines. Latent viruses and pathogens perpetuate the cycle.
4. Case Study: Histamine Blockade as Proof-of-Concept
For 15+ years, the author endured severe scalp lesions, nerve hypersensitivity, cognitive dysfunction, insomnia, and three cardiac arrests (August 12, 2018; 18 months later; August 30, 2023), misdiagnosed as dermatitis or stress. A HSV-1 swab, confirmed by primary care and dermatologist’s office after 5 years of incorrect treatment, revealed the trigger. Topical diphenhydramine (2% Benadryl ointment) for poison ivy, then scalp, initiated healing within 48 hours. Oral diphenhydramine (25 mg daily), with omeprazole for gut balance, sustained remission, alleviating systemic inflammation. This self-taught intervention disrupted the axis, restoring equilibrium.
5. Therapeutic Framework
The Swygert Axis proposes layered interventions, under medical supervision:
H1–H4 Blockade: Diphenhydramine (25–50 mg daily) and omeprazole for H1/H2, cetirizine/loratadine by day; H3 modulators (pitolisant) and H4 antagonists (e.g., JNJ-38559) for deeper effects [9,10].
Anti-Cytokine Agents: Tocilizumab (IL-6) and quercetin reduce inflammation [11].
Viral Containment: Valacyclovir and lysine suppress latency [8].
Supportive Therapies: Low-dose naltrexone and omega-3s aid neurorepair [12].
These embody V = EY, transforming opportunity (Y) into health (V) via equilibrium (E).
6. Real-World Evidence
Antihistamines (H1/H2) relieved long COVID symptoms [13,14]. Preclinical H4 antagonists reduced inflammation [10]. The author’s remission with diphenhydramine (25 mg daily) and kratom’s anti-inflammatory effect underscore accessibility [15].
7. Applications and Research Directions
The Swygert Axis supports:
Biomarkers: Histamine polymorphisms, IL-6/TNF-α dominance, viral PCR, mast cell mediators.
Clinical Trials: Layered H1–H4 therapies for stratified patients.
Swygert Axiology: A new discipline integrating immune-neurovascular care.
8. Conclusion
The Swygert Axis redefines chronic illness as axis collapse, validated by the author’s recovery and literature. Rooted in TSTOEAO’s V = EY, it offers a low-cost, reproducible paradigm. Action is urgent to end preventable suffering.
References
[1] Simons et al. (2023). J Allergy Clin Immunol, 151(1), 15–25. doi:10.1016/j.jaci.2022.10.012
[2] Malone et al. (2021). Front Pharmacol, 12, 699333. doi:10.3389/fphar.2021.699333
[3] Passani et al. (2017). Trends Pharmacol Sci, 38(3), 231–243. doi:10.1016/j.tips.2016.11.008
[4] Zampeli & Tiligada (2009). Br J Pharmacol, 157(1), 24–33. doi:10.1111/j.1476-5381.2009.00150.x
[5] Schirmer et al. (2021). Front Pharmacol, 12, 682613. doi:10.3389/fphar.2021.682613
[6] Theoharides et al. (2022). Clin Rev Allergy Immunol, 62(1), 1–15. doi:10.1007/s12016-021-08876-4
[7] Qu et al. (2021). Int J Mol Sci, 22(16), 8792. doi:10.3390/ijms22168792
[8] Cohen (2020). J Clin Invest, 130(7), 3361–3369. doi:10.1172/JCI136577
[9] Kou et al. (2024). Pharmacol Rev, 76(2), 123–140. doi:10.1124/pharmrev.123.000789
[10] Thurmond et al. (2015). Front Pharmacol, 6, 174. doi:10.3389/fphar.2015.00174
[11] Colunga Biancatelli et al. (2020). Front Immunol, 11, 1451. doi:10.3389/fimmu.2020.01451
[12] Younger et al. (2014). Expert Rev Neurother, 14(10), 1177–1187. doi:10.1586/14737175.2014.983616
[13] Pinto et al. (2022). J Med Virol, 94(10), 4678–4685. doi:10.1002/jmv.27987
[14] Hogan et al. (2022). J Am Organ Nurse Leadersh, 40(2), 45–50. doi:10.1002/aonl.2022.40.issue-2
https://www.fda.gov/drugs/drug-safety-and-availability/faers
Declarations
Funding: None.
Competing Interests: None declared.
Ethics: Based on lived experience and literature; no human subjects research.
Acknowledgements: To the millions suffering—may TSTOEAO’s vision bring hope.
Comments
Post a Comment